Vabomere FDA Approval History
FDA Approved: Yes (First approved August 29, 2017)
Brand name: Vabomere
Generic name: meropenem and vaborbactam
Dosage form: Injection
Previous Name: Carbavance
Company: The Medicines Company
Treatment for: Urinary Tract Infection
Vabomere (meropenem and vaborbactam) is a carbapenem and beta-lactamase inhibitor combination for the treatment of complicated urinary tract infections (cUTIs).
Development timeline for Vabomere
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
